<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Adult preventive services (ages 18-49).&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Adult preventive services (ages 18 - 49). Southfield (MI): Michigan Quality Improvement Consortium; 2013 Mar. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Adult preventive services (ages 18 - 49). Southfield (MI): Michigan Quality Improvement Consortium; 2012 Jan. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Adult physical abuse  (995.81); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled  (250.01); Diphtheria, unspecified  (032.9); General physical examination  (89.7); Human immunodeficiency virus [HIV] disease  (042); Human papillomavirus in conditions classified elsewhere and of unspecified site  (079.4); Major depressive affective disorder, single episode, unspecified  (296.20); Malignant neoplasm of breast (female), unspecified  (174.9); Malignant neoplasm of cervix uteri, unspecified site  (180.9); Malignant neoplasm of colon, unspecified site  (153.9); Malignant neoplasm of rectum  (154.1); Measles without mention of complication  (055.9); Meningococcal infection, unspecified  (036.9); Mumps without mention of complication  (072.9); Obesity, unspecified  (278.00); Other nongonococcal urethritis, chlamydia trachomatis  (099.41); Other venereal diseases due to chlamydia trachomatis, unspecified genitourinary site  (099.55); Overweight  (278.02); Pneumonia due to Streptococcus, unspecified  (481); Pneumonia due to Streptococcus, unspecified  (482.30); Rubella without mention of complication  (056.9); Screening for diabetes mellitus  (V77.1); Tetanus  (037); Tobacco use disorder  (305.1); Unspecified disorder of lipoid metabolism  (272.9); Varicella without mention of complication  (052.9); Viral hepatitis A without mention of hepatic coma  (070.1); Viral hepatitis B without mention of hepatic coma, acute or unspecified, without mention of hepatitis delta  (070.30); Whooping cough due to bordetella pertussis [B. pertussis]  (033.0)"/><FieldValue Value="MSH: AIDS Serodiagnosis ; Alcohol-Related Disorders ; Alcoholism ; Aspirin ; Blood Chemical Analysis ; Blood Pressure Determination ; Body Height ; Body Weight ; Breast Neoplasms ; Chickenpox ; Chickenpox Vaccine ; Chlamydia Infections ; Colorectal Neoplasms ; Counseling ; Diabetes Mellitus ; Diphtheria ; Diphtheria-Tetanus Vaccine ; Diphtheria-Tetanus-acellular Pertussis Vaccines ; Dyslipidemias ; Early Detection of Cancer ; Hepatitis A ; Hepatitis A Vaccines ; Hepatitis B ; Hepatitis B Vaccines ; HIV Infections ; Hypertension ; Immunization ; Immunization Programs ; Immunization Schedule ; Inflammatory Bowel Diseases ; Influenza Vaccines ; Influenza, Human ; Lipid Metabolism Disorders ; Mammography ; Mass Screening ; Measles ; Measles-Mumps-Rubella Vaccine ; Medical History Taking ; Meningococcal Infections ; Meningococcal Vaccines ; Mumps ; Myocardial Infarction ; Obesity ; Overweight ; Papillomavirus Infections ; Papillomavirus Vaccines ; Physical Examination ; Pneumococcal Infections ; Pneumococcal Vaccines ; Pneumonia, Pneumococcal ; Preventive Health Services ; Risk Assessment ; Rubella ; Substance-Related Disorders ; Tetanus ; Tobacco Use Disorder ; Uterine Cervical Neoplasms ; Vaginal Smears ; Whooping Cough "/><FieldValue Value="MTH: AIDS Serodiagnosis measurement ; Alcoholic Intoxication, Chronic ; Aspirin ; Blood Chemical Analysis ; Blood pressure determination ; Body Height ; Body Weight ; Chickenpox ; Chickenpox Vaccine ; Chlamydia Infections ; Chlamydia test kit ; Cholesterol measurement test ; Colorectal Carcinoma ; Counseling ; Diabetes Mellitus ; Diabetes Mellitus screen ; Diphtheria ; Diphtheria-Tetanus Vaccine ; Early Detection of Cancer ; Encounter for screening for diabetes mellitus ; Hepatitis A ; Hepatitis A Vaccines ; Hepatitis B ; Hepatitis B Vaccines ; HIV Infections ; HIV screen ; Human papillomavirus infection in conditions classified elsewhere and of unspecified site ; Hypertensive disease ; Immunization ; Inflammatory Bowel Diseases ; Influenza ; Influenza virus vaccine ; Lipid Metabolism Disorders ; Lipids measurement ; Malignant neoplasm of breast ; Malignant neoplasm of female breast ; Malignant Rectal Neoplasm ; Malignant tumor of cervix ; Malignant tumor of colon ; Mammary Neoplasms ; Mammography ; Measles ; Measles-Mumps-Rubella Vaccine ; Meningococcal Infections ; Meningococcal vaccine ; Mumps ; Myocardial Infarction ; Obesity ; OVERWEIGHT ; Pap smear ; Pertussis ; physical examination ; Pneumococcal vaccine ; Risk Assessment ; Rubella ; Rubella without complication ; Screening for cancer ; Screening for venereal disease ; Streptococcal pneumonia ; Substance abuse problem ; Tetanus ; Tobacco Use Disorder ; Uterine Cervical Neoplasm "/><FieldValue Value="PDQ: acetylsalicyclic acid ; mammography ; obesity ; Pap test ; substance abuse disorder ; tobacco use disorder "/><FieldValue Value="SNOMEDCT_US: Alcohol consumption screening  (171208001); Alcohol-induced organic mental disorder  (29212009); Alcoholism  (284591009); Alcoholism  (66590003); Alcoholism  (7200002); Aspirin  (387458008); Aspirin  (7947003); Blood chemistry  (166312007); Blood pressure taking  (46973005); Body height measure  (50373000); Body weight  (27113001); Chlamydial infection  (105629000); Chlamydial urethritis  (179101003); Chlamydial urethritis  (236683007); Counseling  (129441002); Counseling  (409063005); Diabetes mellitus  (73211009); Diabetes mellitus screening  (171183004); Diphtheria  (276197005); Diphtheria  (397428000); Diphtheria + tetanus + acellular pertussis vaccine  (429321000124106); Diphtheria + tetanus vaccine  (350327004); Diphtheria + tetanus vaccine  (73152006); Disease due to Papilloma virus  (30415006); Disorder of lipid metabolism  (267431006); Dyslipidemia  (370992007); Examination of breast  (46662001); HIV screening  (171121004); Human immunodeficiency virus infection  (86406008); Hyperlipidemia screening  (268552003); Hypertensive disorder  (38341003); Immunization  (127785005); Inflammatory bowel disease  (24526004); Influenza  (6142004); Influenza virus vaccine  (396425006); Influenza virus vaccine  (46233009); Lipids measurement  (104780002); Malignant neoplasm of female breast  (372064008); Malignant neoplasm of rectum, rectosigmoid junction and anus  (187760008); Malignant tumor of breast  (254837009); Malignant tumor of cervix  (363354003); Malignant tumor of colon  (363406005); Malignant tumor of rectum  (363351006); Mammography  (71651007); Measles  (14189004); Measles, mumps and rubella vaccine  (396429000); Measles, mumps and rubella vaccine  (61153008); Meningococcal infectious disease  (23511006); Meningococcus vaccine  (423531006); Meningococcus vaccine  (424891007); Mumps  (240526004); Mumps  (36989005); Mumps without complication  (111870000); Myocardial infarction  (22298006); Neoplasm of breast  (126926005); Neoplasm of large intestine  (126837005); Neoplasm of uterine cervix  (123841004); Obesity  (414915002); Obesity  (414916001); Overweight  (238131007); Pertussis  (27836007); Physical abuse of adult  (371778002); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Pneumococcal infectious disease  (16814004); Pneumococcal vaccine  (333598008); Pneumococcal vaccine  (398730001); Pneumonia due to Streptococcus  (233607000); Pneumonia due to Streptococcus  (34020007); Risk assessment  (225338004); Rubella  (36653000); Rubella without complication  (111867004); Screening for cancer  (15886004); Screening for Chlamydia trachomatis  (442487003); Single major depressive episode  (268620009); Single major depressive episode  (36923009); Substance abuse  (66214007); Tetanus  (276202003); Tetanus  (76902006); Tobacco dependence syndrome  (89765005); Type B viral hepatitis  (66071002); Varicella  (38907003); Varicella virus vaccine  (108729007); Varicella virus vaccine  (396442000); Venereal disease screening  (171128005); Viral hepatitis A without hepatic coma  (111879004); Viral hepatitis, type A  (40468003)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Preventable diseases and conditions, including:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Overweight/obesity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertension &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Myocardial infarction (MI) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dyslipidemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Alcohol and/or tobacco use &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetes mellitus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Colorectal cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cervical cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chlamydial infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Breast cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Human immunodeficiency virus (HIV) infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tetanus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diphtheria &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pertussis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Human papillomavirus (HPV) infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Measles &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mumps &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rubella &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Varicella infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Influenza &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hepatitis A (HepA), hepatitis B (HepB) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Meningococcal infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pneumococcal infection &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Preventive Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Plans" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To achieve significant, measurable improvements in the management of adult preventive services (ages 18 to 49) through the development and implementation of common evidence-based clinical practice guidelines &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To design concise guidelines that are focused on key management components of adult preventive services (ages 18 to 49) to improve outcomes&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adult patients ages 18 to 49 years&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Screening/Prevention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Health maintenance exam (HME), including risk evaluation and counseling for obesity, tobacco use, and alcohol use &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health assessment screening:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Blood pressure (BP) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Aspirin (ASA) use &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cholesterol and lipids &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Diabetes mellitus &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Colorectal cancer &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cervical cancer, pap smear &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chlamydia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Breast cancer &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Human immunodeficiency virus (HIV) infection &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunizations:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Tetanus, diphtheria, and acellular pertussis/tetanus-diphtheria (Tdap/Td) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Human papillomavirus (HPV) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Measles, mumps, and rubella (MMR) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Varicella &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Influenza &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Hepatitis A (HepA), hepatitis B (HepB) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Meningococcal &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pneumococcal &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Michigan Quality Improvement Consortium (MQIC) health care analyst conducts a search of current literature in support of the guideline topic. Computer database searches are used to identify published studies, existing protocols and/or national guidelines on the selected topic developed by organizations such as the American Diabetes Association, American Heart Association, American Academy of Pediatrics, etc. If available, clinical practice guidelines from participating MQIC health plans and Michigan health systems are also used to develop a framework for the new guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For the current update of the guideline the United States Preventive Services Task Force (USPSTF) and Advisory Committee on Immunization Practices (ACIP) databases were searched. No date restrictions were used and no specific inclusion/exclusion criteria were applied.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Using information obtained from literature searches and available health plan guidelines on the designated topic, the Michigan Quality Improvement Consortium (MQIC) health care analyst prepares a draft guideline to be reviewed by the Medical Directors' Committee at one of their scheduled meetings. Priority is given to recommendations with [A] and [B] levels of evidence (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The initial draft guideline is reviewed, evaluated, and revised by the committee, resulting in draft two of the guideline. Additionally, the Michigan Academy of Family Physicians participates in guideline development at the onset of the process and throughout the guideline development procedure. The MQIC guideline feedback form and draft two of the guideline are distributed to the Medical Directors, as well as the MQIC measurement and implementation group members, for review and comments. Feedback from members is collected by the MQIC health care analyst and prepared for review by the Medical Directors' Committee at their next scheduled meeting. The review, evaluation, and revision process with several iterations of the guideline may be repeated over several meetings before consensus is reached on a final draft guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Recommendation Grades*&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A.&lt;/strong&gt; The United States Preventive Services Task Force (USPSTF) recommends the service. There is high certainty that the net benefit is substantial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B.&lt;/strong&gt; The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C.&lt;/strong&gt; The USPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient. There is at least moderate certainty that the net benefit is small.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt;. The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt;. The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*The grade definitions used for this guideline are as defined by the USPSTF.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;When consensus is reached on the final draft guideline, the Medical Directors approve the guideline for external distribution to practitioners with review and comments requested via the Michigan Quality Improvement Consortium (MQIC) health plans (health care analyst distributes final draft to Medical Directors' Committee, measurement and implementation groups to solicit feedback).&lt;/p&gt;&#xA;&lt;p&gt;The MQIC health care analyst also forwards the approved guideline draft to appropriate state medical specialty societies and physicians with expertise in the related field for their input. After all feedback is received from external reviews, it is presented for discussion at the next scheduled committee meeting. Based on feedback, subsequent guideline review, evaluation, and revision may be required prior to final guideline approval.&lt;/p&gt;&#xA;&lt;p&gt;The MQIC Medical Directors approved this updated guideline in March 2013.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The recommendation grades (&lt;strong&gt;A-D, &lt;/strong&gt;and&lt;strong&gt; I&lt;/strong&gt;) are provided for the most significant recommendations and are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Health Assessment Screening, History, and Counseling&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;One health maintenance exam (HME) every 1 to 5 years according to risk status, including: Height, weight, and body mass index (BMI) &lt;strong&gt;[B]&lt;/strong&gt;; Risk evaluation and counseling for obesity (BMI &amp;ge;30) &lt;strong&gt;[B]&lt;/strong&gt;, tobacco use &lt;strong&gt;[A]&lt;/strong&gt;, and alcohol use &lt;strong&gt;[B]&lt;/strong&gt;. See the National Guideline Clearinghouse (NGC) summaries of the Michigan Quality Improvement Consortium (MQIC) guidelines: &lt;a href=&quot;/content.aspx?id=46654&quot; title=&quot;Guideline #9933&quot;&gt;Management of overweight and obesity in the adult&lt;/a&gt;, &lt;a href=&quot;/content.aspx?id=47550&quot; titlte=&quot;Guideline #10086&quot;&gt;Tobacco control&lt;/a&gt; and &lt;a href=&quot;/content.aspx?id=47911&quot; title=&quot;Guideline #10317&quot;&gt;Screening, diagnosis and referral for substance use disorders&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Blood Pressure (BP) Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Screen for high BP in adults 18 years and older &lt;strong&gt;[A]&lt;/strong&gt;. Screen every two years if BP &amp;le;120/80 mm Hg. Annually if BP 120-139/80-89 mm Hg, and more frequently if warranted.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Aspirin (ASA) Use&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommend the use of ASA for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarction (MI) outweighs the potential harm due to an increase in gastrointestinal hemorrhage &lt;strong&gt;[A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cholesterol and Lipid Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Measure a fasting lipoprotein profile (i.e., total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C]) in men aged 35 years and older &lt;strong&gt;[A]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Measure a fasting lipoprotein profile in women aged 45 years and older if they are at increased risk for coronary heart disease (CHD) (i.e., diabetes, family history of cardiovascular disease before age 50 in male relatives or age 60 in female relatives, tobacco use, hypertension, BMI &amp;ge;30) &lt;strong&gt;[A]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screen men aged 20 to 35 and women aged 20 to 45 if they are at increased risk for CHD &lt;strong&gt;[B]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screen every five years for low risk adults if initial test normal; consider more frequent screening in individuals at increased risk. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Diabetes Mellitus Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Screen for type 2 diabetes in asymptomatic adults with sustained BP (either treated or untreated) greater than 135/80 mm Hg &lt;strong&gt;[B]&lt;/strong&gt;. Screen every three years. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In persons with BP &amp;le;135/80 mm Hg, screen on an individual basis according to CHD risks and benefits. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Colorectal Cancer Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;No requirement unless high risk (e.g., chronic inflammatory bowel disease &lt;strong&gt;[B]&lt;/strong&gt;; first degree relatives who have had early-onset colorectal cancer; specific inherited syndromes, Lynch syndrome).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cervical Cancer Screening, Pap Smear&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Screen women age 21 to 65 years with cytology every 3 years, or, for women age 30 to 65 years who want to lengthen the screening interval, screen with a combination of cytology and human papillomavirus (HPV) testing every 5 years &lt;strong&gt;[A]&lt;/strong&gt;. Testing for HPV before age 30 not recommended &lt;strong&gt;[D]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine pap smear screening not recommended in women who have had a total hysterectomy for benign disease, or age less than 21 &lt;strong&gt;[D]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Chlamydia Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Recommended for all sexually active non-pregnant women aged 24 and younger and for older non-pregnant women who are at increased risk (i.e., new or multiple sexual partners, history of sexually transmitted diseases, not using condoms consistently or correctly) &lt;strong&gt;[A]&lt;/strong&gt;. Screen at least annually if at increased risk. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recommend screening for all pregnant women aged 24 and younger and for older pregnant women who are at increased risk &lt;strong&gt;[B]&lt;/strong&gt;. Screen at first prenatal visit. If continued risk, screen again in third trimester. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine screening not recommended for women aged 25 and older, whether or not pregnant, if they are not at increased risk &lt;strong&gt;[C]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Breast Cancer Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Biennial mammography screening before the age of 50 years should be an individual decision taking patient context into account &lt;strong&gt;[C]&lt;/strong&gt;&lt;sup&gt;1&lt;/sup&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The current evidence is insufficient to assess the additional benefits and harms of either clinical breast examination (CBE), digital mammography, or magnetic resonance imaging (MRI), beyond screening mammography in women 40 years or older &lt;strong&gt;[I]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;1&lt;/sup&gt; The Affordable Care Act considers mammography at age 40 an &quot;essential benefit.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Human Immunodeficiency Virus (HIV) Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Screen all patients 15 to 65 years of age &lt;strong&gt;[A]&lt;/strong&gt;. Screen all increased risk patients (no age limit) &lt;strong&gt;[A]&lt;/strong&gt; annually.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Immunizations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consult the &lt;a href=&quot;http://www.cdc.gov/vaccines/acip/recs/index.html&quot; title=&quot;ACIP Web site&quot; target=&quot;_blank&quot;&gt;Advisory Committee on Immunization Practices (ACIP) Web site&lt;/a&gt; for up-to-date recommendations and other vaccine indications based on medical and other indications.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Tetanus, Diphtheria, and Acellular Pertussis/Tetanus-diphtheria (Tdap/Td)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;After primary series, Td every 10 years. Give Tdap once after age 12.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;HPV&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Females age &amp;le;26 years should receive HPV4 or HPV2. Males age &amp;le;21 years may receive HPV4. Males age 22 to 26 may receive HPV4.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Measles, Mumps, and Rubella (MMR)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;One or two doses for persons who lack history of immunization or convincing history of infection.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Varicella&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two doses for persons who lack history of immunization or convincing history of infection.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Influenza&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Annual vaccine.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hepatitis A (HepA), Hepatitis B (HepB), Meningococcal, Pneumococcal&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If risk factors present.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation Grades*&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt;. The United States Preventive Services Task Force (USPSTF) recommends the service. There is high certainty that the net benefit is substantial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt;. The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt;. The USPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient. There is at least moderate certainty that the net benefit is small.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt;. The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I.&lt;/strong&gt; The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*The grade definitions used for this guideline are as defined by the USPSTF.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence is provided for the most significant recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline is based on several sources, including: The Guide to Clinical Preventive Services 2012, Recommendations of the U.S. Preventive Services Task Force (&lt;a href=&quot;http://www.ahrq.gov/clinic/pocketgd.htm&quot; title=&quot;AHRQ Web site&quot; target=&quot;_blank&quot;&gt;http://www.ahrq.gov/clinic/pocketgd.htm&lt;/a&gt;) and the Advisory Committee on Immunization Practices (ACIP) 2011 Immunization Recommendations (&lt;a href=&quot;http://www.cdc.gov/&quot; title=&quot;CDC Web site&quot; target=&quot;_blank&quot;&gt;www.cdc.gov&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Through a collaborative approach to developing and implementing common clinical practice guidelines and performance measures for adult preventive services (ages 18 to 49), Michigan health plans will achieve consistent delivery of evidence-based services and better health outcomes. This approach also will augment the practice environment for physicians by reducing the administrative burdens imposed by compliance with diverse health plan guidelines and associated requirements.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Potential adverse effects of aspirin (ASA) (e.g., gastrointestinal hemorrhage)&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline lists core management steps. Individual patient considerations and advances in medical science may supersede or modify these recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Approved Michigan Quality Improvement Consortium (MQIC) guidelines are disseminated through email, U.S. mail, and websites.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst prepares approved guidelines for distribution. Portable Document Format (PDF) versions of the guidelines are used for distribution.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst distributes approved guidelines to MQIC membership via email.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to Web site vendor to post approved guidelines to the &lt;a href=&quot;http://www.mqic.org/&quot; title=&quot;MQIC Web site&quot;&gt;MQIC Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst completes an annual statewide postcard mailing to physicians in all areas of medicine including primary care and specialties. The postcard provides the complete list of MQIC guidelines and includes which guidelines have been recently revised, which are coming up for revision, and any new published guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The statewide mailing list is derived from the Blue Cross Blue Shield of Michigan (BCBSM) provider database. Approximately 95% of the state's M.D.'s and 96% of the state's D.O.'s are included in the database.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to the National Guideline Clearinghouse (NGC) to post approved guidelines to the &lt;a href=&quot;http://www.guideline.gov&quot; title=&quot;NGC Web site&quot; target=&quot;_blank&quot;&gt;NGC Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Adult preventive services (ages 18 - 49). Southfield (MI): Michigan Quality Improvement Consortium; 2013 Mar. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is based on several sources, including: The Guide to Clinical Preventive Services 2012, Recommendations of the U.S. Preventive Services Task Force (&lt;a href=&quot;http://www.ahrq.gov/clinic/pocketgd.htm&quot; title=&quot;AHRQ Web site&quot; target=&quot;_blank&quot;&gt;http://www.ahrq.gov/clinic/pocketgd.htm&lt;/a&gt;) and the Advisory Committee on Immunization Practices (ACIP) 2011 Immunization Recommendations (&lt;a href=&quot;http://www.cdc.gov/&quot; title=&quot;CDC Web site&quot; target=&quot;_blank&quot;&gt;www.cdc.gov&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2005 Jul (revised 2013 Mar)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Michigan Quality Improvement Consortium - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium Medical Directors' Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Physician representatives from the 13 participating Michigan Quality Improvement Consortium health plans, Michigan State Medical Society, Michigan Osteopathic Association, Michigan Association of Health Plans, Michigan Department of Community Health, Michigan Peer Review Organization, and the University of Michigan Health System&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Standard disclosure is requested from all individuals participating in the Michigan Quality Improvement Consortium (MQIC) guideline development process, including those parties who are solicited for guideline feedback (e.g., health plans, medical specialty societies). Additionally, members of the MQIC Medical Directors' Committee are asked to disclose all commercial relationships as well.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Adult preventive services (ages 18 - 49). Southfield (MI): Michigan Quality Improvement Consortium; 2012 Jan. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.mqic.org/pdf/mqic_adult_preventive_services_ages_18_to_49_cpg.pdf&quot; title=&quot;MQIC Web site&quot;&gt;Michigan Quality Improvement Consortium Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on November 28, 2005. The updated information was verified by the guideline developer on December 19, 2005. This NGC summary was updated by ECRI on October 13, 2006. The updated information was verified by the guideline developer on November 3, 2006. This NGC summary was updated by ECRI Institute on November 26, 2008. The updated information was verified by the guideline developer on December 4, 2008. This NGC summary was updated by ECRI Institute on July 22, 2011. The updated information was verified by the guideline developer on September 2, 2011. This NGC summary was updated by ECRI Institute on May 29, 2012. The updated information was verified by the guideline developer on June 25, 2012. This NGC summary was updated by ECRI Institute on August 22, 2013. The updated information was verified by the guideline developer on October 2, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which may be reproduced with the citation developed by the Michigan Quality Improvement Consortium.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
